IN2015DN01483A - - Google Patents

Info

Publication number
IN2015DN01483A
IN2015DN01483A IN1483DEN2015A IN2015DN01483A IN 2015DN01483 A IN2015DN01483 A IN 2015DN01483A IN 1483DEN2015 A IN1483DEN2015 A IN 1483DEN2015A IN 2015DN01483 A IN2015DN01483 A IN 2015DN01483A
Authority
IN
India
Prior art keywords
stimulation
component
vaccines
antigen
induced
Prior art date
Application number
Other languages
English (en)
Inventor
Geoffrey W Hoffmann
Sybille Muller
Original Assignee
Network Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Network Immunology Inc filed Critical Network Immunology Inc
Publication of IN2015DN01483A publication Critical patent/IN2015DN01483A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN1483DEN2015 2012-08-08 2013-08-08 IN2015DN01483A (enExample)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261681040P 2012-08-08 2012-08-08
US201261727539P 2012-11-16 2012-11-16
US201361801153P 2013-03-15 2013-03-15
PCT/CA2013/000710 WO2014022924A1 (en) 2012-08-08 2013-08-08 A method for the induction of an immune response

Publications (1)

Publication Number Publication Date
IN2015DN01483A true IN2015DN01483A (enExample) 2015-07-03

Family

ID=50067331

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1483DEN2015 IN2015DN01483A (enExample) 2012-08-08 2013-08-08

Country Status (5)

Country Link
US (1) US20150216973A1 (enExample)
EP (1) EP2882455A4 (enExample)
CA (1) CA2881317A1 (enExample)
IN (1) IN2015DN01483A (enExample)
WO (1) WO2014022924A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847591B (zh) * 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE255902T1 (de) * 1992-03-09 2003-12-15 San Diego Regional Cancer Ct Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten
US20040180050A1 (en) * 1994-05-31 2004-09-16 Hoffman Geoffrey W. Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease
US6057421A (en) * 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
WO2003059953A2 (en) * 2002-01-17 2003-07-24 Polymun Scientific Immunbiologische Forschung Gmbh Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
US20100150960A1 (en) * 2006-09-22 2010-06-17 The United States Of America, As Represented By The Secretary,Department Of Health And Human Servi Compositions and methods for chitosan enhanced immune response

Also Published As

Publication number Publication date
CA2881317A1 (en) 2014-02-13
WO2014022924A1 (en) 2014-02-13
EP2882455A1 (en) 2015-06-17
EP2882455A4 (en) 2016-03-23
US20150216973A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
CO2018004321A2 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
EA201800108A1 (ru) Вакцинные композиции для профилактики абровирусных инфекций
ZA201805295B (en) Methods for enhancing efficacy of a vaccine by administering an il¿4r antagonist
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
MX2015014500A (es) Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9.
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
MX377363B (es) Composición de vacuna.
SG11201605691VA (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
EA201790507A1 (ru) Способы и композиции для усиления иммунных ответов
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
EP3571288A4 (en) INDUCTION OF PROTECTIVE IMMUNITY AGAINST ANTIGENS
PL3402802T3 (pl) Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym
MX2017016651A (es) Anticuerpos contra csf-1r humano para su uso en la induccion de linfocitosis en linfomas o leucemias.
SG11201609965XA (en) Antibody guided vaccines and methods of use for generation of rapid mature immune responses
EP2968500A4 (en) VACCINES WITH ONE ANTIGEN AND INTERLEUKIN-23 AS ADJUVANS
WO2017053525A3 (en) Influenza vaccine and therapy
PL3024935T3 (pl) Przyspieszenie reakcji immunologicznej u ptaków indukowanej przez wektor wirusowy
MX2019008779A (es) Antigenos de pseudomonas y combinaciones de antigenos.
WO2013173256A3 (en) New and improved influenza vaccines
ES2503516R1 (es) Complejo inmunogénico para vacunación y método de obtención
IN2015DN01483A (enExample)
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.